Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

June 14, 2019

Primary Completion Date

May 24, 2024

Study Completion Date

August 13, 2024

Conditions
Asthma
Interventions
BIOLOGICAL

Experimental: Tezepelumab

Tezepelumab subcutaneous injection

OTHER

Placebo

Placebo subcutaneous injection

Trial Locations (72)

1100

Research Site, Quezon City

5000

Research Site, Iloilo City

10050

Research Site, Hohhot

14010

Research Site, Baotou

16499

Research Site, Suwon

28644

Research Site, Cheongju-si

42415

Research Site, Daegu

54907

Research Site, Jeonju

100020

Research Site, Beijing

100029

Research Site, Beijing

100070

Research Site, Beijing

100730

Research Site, Beijing

100853

Research Site, Beijing

110004

Research Site, Shengyang

110015

Research Site, Shenyang

130021

Research Site, Changchun

133500

Research Site, Hefei

200025

Research Site, Shanghai

200032

Research Site, Shanghai

200050

Research Site, Shanghai

210009

Research Site, Nanjing

210029

Research Site, Nanjing

221000

Research Site, Xuzhou

221009

Research Site, Xuzhou

225001

Research Site, Yangzhou

250013

Research Site, Jinan

255036

Research Site, Zibo

261041

Research Site, Weifang

300192

Research Site, Tianjin

310020

Research Site, Hangzhou

313003

Research Site, Huzhou

317000

Research Site, Linhai

321000

Research Site, Jinhua

325027

Research Site, Wenzhou

330006

Research Site, Nanchang

350001

Research Site, Fuzhou

362000

Research Site, Quanzhou

400000

Research Site, Chongqing

400016

Research Site, Chongqing

400038

Research Site, Chongqing

410008

Research Site, Changsha

410011

Research Site, Changsha

421001

Research Site, Hengyang

430022

Research Site, Wuhan

430030

Research Site, Wuhan

430033

Research Site, Wuhan

450000

Research Site, Zhengzhou

510080

Research Site, Guangzhou

510120

Research Site, Guangzhou

510515

Research Site, Guangzhou

518035

Research Site, Shenzhen

519099

Research Site, Zhuhai

530007

Research Site, Nanning

550004

Research Site, Guiyang

563100

Research Site, Zunyi

570311

Research Site, Haikou

610041

Research Site, Chengdu

650032

Research Site, Kunming

710004

Research Site, Xi'an

730000

Research Site, Lanzhou

810007

Research Site, Xining

830054

Research Site, Ürümqi

1000096

Research Site, Beijing

2100008

Research Site, Nanjing

Unknown

Research Site, Guangzhou

010017

Research Site, Hohhot

CN-276003

Research Site, Linyi

050000

Research Site, Shijiazhuang

03312

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

06591

Research Site, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

AstraZeneca

INDUSTRY